Mihael Hristos Polymeropoulos net worth and biography

Mihael Polymeropoulos Biography and Net Worth

Mihael H. Polymeropoulos, MD, cofounded Vanda and has served as President, Chief Executive Officer and a Director since May 2003. From 1998 to 2003, Dr. Polymeropoulos was Vice President and Head of the Pharmacogenetics Department at Novartis AG. Prior to Novartis, he served as Chief of the Gene Mapping Section, Laboratory of Genetic Disease Research, National Human Genome Research Institute, from 1992 to 1998. Dr. Polymeropoulos is the cofounder of the Integrated Molecular Analysis of Genome Expression (I.M.A.G.E.) Consortium. Dr. Polymeropoulos holds a degree in Medicine from the University of Patras.

What is Mihael Hristos Polymeropoulos' net worth?: The estimated net worth of Mihael Hristos Polymeropoulos is at least $10.99 million as of March 5th, 2025. Dr. Polymeropoulos owns 2,285,731 shares of Vanda Pharmaceuticals stock worth more than $10,994,366 as of March 25th. This net worth evaluation does not reflect any other investments that Dr. Polymeropoulos may own. Additionally, Dr. Polymeropoulos receives an annual salary of $1,920,000.00 as CEO at Vanda Pharmaceuticals. Learn More about Mihael Hristos Polymeropoulos' net worth.
How old is Mihael Hristos Polymeropoulos?: Dr. Polymeropoulos is currently 64 years old. There are 4 older executives and no younger executives at Vanda Pharmaceuticals. Learn More on Mihael Hristos Polymeropoulos' age.
What is Mihael Hristos Polymeropoulos' salary?: As the CEO of Vanda Pharmaceuticals Inc., Dr. Polymeropoulos earns $1,920,000.00 per year. Learn More on Mihael Hristos Polymeropoulos' salary.
How do I contact Mihael Hristos Polymeropoulos?: The corporate mailing address for Dr. Polymeropoulos and other Vanda Pharmaceuticals executives is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. Vanda Pharmaceuticals can also be reached via phone at (202) 734-3400 and via email at pr@vandapharma.com. Learn More on Mihael Hristos Polymeropoulos' contact information.
Has Mihael Hristos Polymeropoulos been buying or selling shares of Vanda Pharmaceuticals?: Over the course of the past ninety days, Mihael Hristos Polymeropoulos has bought $142,400.00 in shares of Vanda Pharmaceuticals stock. Most recently, on Wednesday, March 5th, Mihael Hristos Polymeropoulos bought 10,000 shares of Vanda Pharmaceuticals stock. The stock was acquired at an average cost of $5.02 per share, with a total value of $50,200.00. Following the completion of the transaction, the chief executive officer now directly owns 2,285,731 shares of the company's stock, valued at $11,474,369.62. Learn More on Mihael Hristos Polymeropoulos' trading history.
Who are Vanda Pharmaceuticals' active insiders?: Vanda Pharmaceuticals' insider roster includes Phaedra Chrousos (Director), Aranthan Jones, II (Insider), Stephen Mitchell (Director), Kevin Moran (CFO), Mihael Polymeropoulos (CEO), and Joakim Wijkstrom (CMO). Learn More on Vanda Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vanda Pharmaceuticals?: In the last twelve months, Vanda Pharmaceuticals insiders bought shares 4 times. They purchased a total of 32,000 shares worth more than $151,180.00. In the last twelve months, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 7,251 shares worth more than $39,175.92. The most recent insider tranaction occured on March, 5th when CEO Mihael Hristos Polymeropoulos bought 10,000 shares worth more than $50,200.00. Insiders at Vanda Pharmaceuticals own 8.9% of the company. Learn More about insider trades at Vanda Pharmaceuticals.
Information on this page was last updated on 3/5/2025.

Mihael Hristos Polymeropoulos Insider Trading History at Vanda Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/5/2025	Buy	10,000	$5.02	$50,200.00	2,285,731
2/28/2025	Buy	10,000	$4.76	$47,600.00	2,361,730
2/25/2025	Buy	10,000	$4.46	$44,600.00	2,331,730
3/2/2023	Sell	22,426	$6.23	$139,713.98	1,499,440
12/5/2022	Sell	47,650	$10.62	$506,043.00	1,379,751
3/1/2022	Sell	7,508	$11.19	$84,014.52
12/1/2021	Sell	46,200	$16.00	$739,200.00
3/8/2021	Sell	175,000	$18.00	$3,150,000.00	1,221,062
12/15/2020	Sell	125,252	$13.04	$1,633,286.08
1/2/2020	Sell	9,467	$16.00	$151,472.00	1,234,579
5/21/2019	Sell	72,872	$15.34	$1,117,856.48	1,276,343
5/17/2019	Sell	77,225	$15.56	$1,201,621.00	1,276,343
3/4/2019	Sell	38,166	$19.41	$740,802.06	1,217,136
3/1/2019	Sell	6,500	$20.22	$131,430.00	1,217,136
1/3/2019	Sell	15,236	$26.36	$401,620.96	1,178,872
3/1/2018	Sell	60,966	$18.72	$1,141,283.52	1,243,838
1/2/2018	Sell	191,760	$15.30	$2,933,928.00	1,031,848
1/4/2016	Sell	21,353	$8.96	$191,322.88	839,178
9/10/2015	Sell	131,739	$12.68	$1,670,450.52	816,781
5/22/2015	Sell	186,395	$10.36	$1,931,052.20

See Full Table

Mihael Hristos Polymeropoulos Buying and Selling Activity at Vanda Pharmaceuticals

Vanda Pharmaceuticals Company Overview

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Today's Range

Now: $4.81

$4.74

$4.87

50 Day Range

MA: $4.65

$4.31

$5.13

2 Week Range

Now: $4.81

$3.86

$6.75

Volume

342,759 shs

Average Volume

1,132,697 shs

Market Capitalization

$280.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Mihael Polymeropoulos Biography and Net Worth

What is Mihael Hristos Polymeropoulos' net worth?

How old is Mihael Hristos Polymeropoulos?

What is Mihael Hristos Polymeropoulos' salary?

How do I contact Mihael Hristos Polymeropoulos?

Has Mihael Hristos Polymeropoulos been buying or selling shares of Vanda Pharmaceuticals?

Who are Vanda Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Vanda Pharmaceuticals?